Skip to main content

Advertisement

Table 2 Clinical features of patients in the validation experiments

From: Predicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer

Clinical features IHC patients (n = 95) ELISA patients (n = 68)
Age (range, years) 67 (26-81) 61 (29-83)
Gender (male/female) 51/44 43/25
Site   
Ascending colon 32 (33.7%) 13 (19.1%)
Descending colon 1 (1%) 4 (5.9%)
Tranverse colon 0 (0%) 2 (2.9%)
Sigmoid colon 31 (32.6%) 25 (36.8%)
Rectum 31 (32.6%) 24 (35.3%)
Stage of CRC at diagnosis   
Stage I 1 (1%) 3 (4.4%)
Stage II 14 (14.7%) 8 (11.8%)
Stage III 34 (35.8%) 14 (20.6%)
Stage IV 46 (48.4%) 43 (63.2%)
Differentiation   
Well 5 (5.3%) 3 (4.4%)
Moderately 67 (70.5%) 39 (57.4%)
Poorly 19 (20%) 15 (22%)
Unknown 4 (4.2%) 11 (16.2%)
Previous chemotherapy in Neoadjuvant/Adjuvant setting   
Yes 33 (34.7%) 20 (29.4%)
No 62 (65.3%) 48 (70.6%)
Chemotherapy for mCRC   
FOLFOX/FLOX 35 (36.8%) 26 (38.2%)
FOLFIRI 15 (15.8%) 11 (16.2%)
Xelox 20 (21.1%) 22 (32.4%)
5FU/Xeloda 25 (26.3%) 9 (13.2%)
Microsatellite instability 7 (8%) 2 (3%)
Yes 64 (67%) 50 (73%)
No 24 (25%) 16 (24%)
Unknown   
Maintenance bevacizumab   
Yes 38 (40%) 25 (36.8%)
No 57 (60%) 43 (63.2%)
PFS, median (range, days) 340 (34-1655) 338 (43-1819)
OS, median (range, days) 784 (78-2110) 653 (98-1819)
Duration of bevacizumab, median, days (range) 242 (12-1169) 238 (12-1245)